TAIPEI, Taiwan – As the momentum surrounding high-growth Asian markets seemingly slows, the standing of Taiwan as an innovation and financing center for biotech interests is still strong, at least on the basis of regional comparison. But while public capital markets are vibrant and local valuations high, big international investors remain largely elusive. So say speakers at the Biologics World Taiwan 2015 conference.